Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

n US dollars. All currency figures reported in this document, including comparative figures, are reported in US dollars, unless otherwise specified.

For the three-month period ended December 31, 2007, the net loss amounted to $16,097,000 ($0.33 per share), compared to $17,011,000 ($0.44 per share) for the corresponding period in the previous year. For the year ended December 31, 2007, the net loss amounted to $81,486,000 ($1.85 per share), compared to $66,469,000 ($1.72 per share) for the same period the previous year.

The net loss for the year ended December 31, 2007, includes a non-recurring charge in the second quarter of fiscal 2007 under Canadian GAAP of $10,430,000 relating to the $40 million 5% senior subordinated convertible notes, which were fully converted into common shares during the second quarter of 2007. In total, accretion expense amounted to $15,751,000 for the year ended December 31, 2007.

Revenue from collaboration agreement amounted to $206,000 for the current quarter ($1,119,000 for the year), compared to $497,000 for the same period in the previous year ($2,106,000 for the year). This revenue is earned under the agreement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product candidate for the treatment of Amyloid A (AA) amyloidosis. Revenue recognized is in respect of the non-refundable upfront payment received from Centocor, which is being amortized over the estimated period through to the anticipated regulatory approval date of the investigational product candidate. The estimated period is subject to change based on additional information that the Company may receive periodically. The other portion of the upfront payment received from Centocor ($6,000,000) has been classified as deferred revenue and is not being amortized as earned revenue given that it is potentially refundable. In the event that the Company receives an approval letter issued by the US Food and Drug Adminis
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... to use a laser to measure people,s blood sugar, ... to a portable size, the technique could allow diabetics ... blood. , "We are working hard to turn engineering ... their daily lives," said Claire Gmachl, the Eugene Higgins ... "With this work we hope to improve the lives ...
(Date:8/21/2014)... a genetically engineered line of mice that is expected ... Alzheimer,s and other diseases. , The mice carry ... in response to different calcium levels. This will allow ... to be studied in a new way. , "This ... brain works," said Petr Tvrdik, Ph.D., a research ...
(Date:8/21/2014)... 21, 2014 Entries are now open ... only comprehensive national awards program totally dedicated to recognizing ... and executive leadership. The entry deadline is Oct. 17. ... Estate Insights™, the first and only national magazine entirely ... investment. , “We launched the HREI Insights Awards program ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Black Americans are ... racial groups battling the blood sugar disease, a new ... National Health and Nutrition Examination Survey, which evaluates about ... the highest rates of a condition known as diabetic ... blindness in people with diabetes. Diabetic macular edema ...
(Date:8/21/2014)... According to the new report “Waterborne Coatings ... PTFE, PVDF, PVDC, & Others), by Application (Architectural, ... & Others) - Global Forecast to 2019” published ... estimated to reach $77,838.71 Million by 2019. , ... spread through 225 Slides and in-depth TOC on ...
Breaking Medicine News(10 mins):Health News:Laser device may end pin pricks, improve quality of life for diabetics 2Health News:Laser device may end pin pricks, improve quality of life for diabetics 3Health News:Mouse model for epilepsy, Alzheimer's gives window into the working brain 2Health News:Entries Open for 2014 HREI Insights Awards™ 2Health News:Entries Open for 2014 HREI Insights Awards™ 3Health News:Entries Open for 2014 HREI Insights Awards™ 4Health News:Blacks May Face Higher Risk of Diabetes-Linked Vision Loss 2Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 2Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 3Health News:Waterborne Coatings Market worth $77,838.71 Million by 2019 – New Report by MarketsandMarkets 4
... Ohio State University Medical Center Implants Two Patients ... Clinical TrialSYDNEY, and TUSTIN, Calif., April 21 Sunshine ... on innovative heart assist technologies, announced today that The ... Ohio has successfully completed the first two implants of ...
... Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), ... device to treat infectious disease, today announced ... to lead its investor relations outreach programs. ... first medical device that can selectively remove ...
... Extend National Diabetes Awareness Campaign in Six Additional CitiesBRIDGEWATER, ... star Ben Vereen will reprise his role as a ... Diabetes Awareness with sanofi-aventis U.S. to share his ... extend the national campaign he kicked off in September ...
... site to help raise awareness of deadliest form of ... of Skin Cancer Awareness Month and the increasing incidence ... Society for Dermatologic Surgery (ASDS) has created a free ... Facebook site. The kit and site were created to ...
... cord injuries much more common than thought , , TUESDAY, April ... million people, live with some form of paralysis, a new ... now, said Joseph Canose, vice president of quality of life ... survey Tuesday. The foundation was created by the late actor ...
... Money-Saving Options Now Available through Schiff(R) Loyalty RewardsSALT LAKE ... the most trusted and respected brands in the nutritional ... Schiff(R) Loyalty Rewards. The new incentive program offers ... Schiff(R) Glucosamine product purchased (at participating retailers). These ...
Cached Medicine News:Health News:First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 2Health News:First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 3Health News:First Patients in United States Receive Innovative Device to Treat Moderate Heart Failure 4Health News:Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs 2Health News:Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs 3Health News:Video: American Performing Icon Ben Vereen Encourages People to 'Take the Stage' and Act on Their Diabetes in 2009 2Health News:Video: American Performing Icon Ben Vereen Encourages People to 'Take the Stage' and Act on Their Diabetes in 2009 3Health News:Video: American Performing Icon Ben Vereen Encourages People to 'Take the Stage' and Act on Their Diabetes in 2009 4Health News:The ASDS Introduces the First At-Home Skin Cancer Exam Kit 2Health News:One in 50 Americans Lives With Paralysis 2Health News:One in 50 Americans Lives With Paralysis 3Health News:Schiff(R) Unveils Loyalty Program to Reward Valued Customers 2
(Date:8/21/2014)... R.I. , Aug. 21, 2014 CVS Caremark ... tender results, applicable Reference Yields and consideration payable in connection ... commenced on August 7, 2014 for (1) any and all ... All Notes") and (2) up to a maximum amount of ... 2041 and 5.750% Senior Notes due 2017 (collectively, the "Maximum ...
(Date:8/21/2014)... , Aug. 21, 2014 Professional Compounding ... paediatric medicine by awarding the three best scientific ... initiative (EuPFI) conference . The Formulating Better ... 18 in Athens, Greece , ... students and professionals, from which three winners will ...
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3
... Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: ... of the peer reviewed journal, Leukemia & ... of a phase I/II clinical trial evaluating the ... in treating patients with aggressive non-Hodgkin,s lymphoma ("NHL") ...
... BASKING RIDGE, N.J., April 3, 2011 Regado Biosciences, ... antithrombotic aptamers with active control agents, announced today the ... of the company,s lead product, the anticoagulation system REG1, ... Cardiology 2011 60th Annual Scientific Session & Expo in ...
Cached Medicine Technology:Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 2Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 3Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 4Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 5Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 6Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 2Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 3Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 4Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 5
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems...
... TT™ offers the ultimate research level wireless ... knowledgeable clinician and researcher today. Offering superb ... to meet your desired footprint requirements. Choose ... display live data both in the room ...
... diagnostic capabilities combined with ease of use ... in its class. Ideal for office or ... system for Uroflowmetry, cystometry, leak point pressure, ... are available which make the OM-5 flexible ...
... diagnostic capabilities combined with ease of use ... in its class. Ideal for office or ... system for Uroflowmetry, cystometry, leak point pressure, ... are available which make the OM-5 flexible ...
Medicine Products: